# Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

> **NCT01147250** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 6068 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Lixisenatide (AVE0010)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01147250
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 6068 (ACTUAL)
- **Last updated:** 2016-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147250, "Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT01147250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*